Wholesale Distribution of Pharmaceuticals
We can provide a professional service of:
- Contract Responsible Person (RP) / Deputy RP
- Wholesale Distribution Authorisation – WDA Application
- Good Distribution Practices (GDP) Compliance
- GAP Analysis and Pre-Inspection Audits
- GDP/ RP Training
- Quality Systems – Build, maintain and the maintenance
- Risk Assessment – Development and mitigation
- Audit Planning – Delivery and Corrective Action
Flexible Training and Workshops
We can offer a wide range of courses presented by professional trainers. Our courses are filled with informative and inter-active workshop content.
Pharmacist and Pharmacies
We can help entrepreneurs gain their own pharmacy by aiding with:
- NHS Contract Application
- GPhC Registration
- Standard Operating Procedures (SOP)
- Recruitment
Is your current pharmacy business at risk? We can consult you on:
- Scoping gaps in the local pharmacy services provision?
- “SWOT” analysis, bespoke marketing plan
- Essential Services Support
- GPhC Inspection preparation
- Automation and Optimisation
- Business Development
Care Quality Commission
We can be your ‘one stop shop’ for CQC Registration and Compliance. We can help with the following:
- CQC registration
- Documentation
- Quality Management Systems
- Pre Audit Analysis
- Risk Profiling and Compliance
- Bespoke Consultancy
- Business improvement
- Training and practical implementation
Latest News
Do you know the GPhC Standards you must adhere to when operating a pharmacy? Part 2, Principle 2 Staffing.
When operating a pharmacy, the General Pharmaceutical Council (GPhC) will come and inspect you against the pharmacy standards, do you know what evidence you will need to present to demonstrate how your pharmacy adheres to the standards?
RegulatoryConnect The MHRA’s new ‘Front Door’
The MHRA have made the first release of their RegulatoryConnect service available which allows tracking of the submission status of product licence applications but will soon offer much more.
New Valproate safety measures
The Medicines and Healthcare products Regulatory Agency (MHRA) announced that from the 31st of January 2024 new regulatory measures have been implemented to ensure that the known harms associated with valproate use are reduced.